

Disclosures

Personal Commercial (10)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Edwards Lifesciences	Other - Member national patient selection committee for CLASP studies using PASCAL device to reduce mitral regurgitation	None (\$0)	Valvular Heart Disease
Edwards Lifesciences	Research/Research Grants	None (\$0)	Valvular Heart Disease
Evalve/Abbott Structural Heart Disease	Research/Research Grants	None (\$0)	Invasive CV Angio and Interventions
Holistic	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Medtronic	Research/Research Grants	None (\$0)	Valvular Heart Disease
Philips Healthcare	Other - Royalty payments on patented coronary software application	Significant (>= \$5,000)	Invasive CV Angio and Interventions
Philips HealthCare	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Philips HealthCare	Research/Research Grants	None (\$0)	Other
St Jude Medical Corp now Abbott Vascular	Research/Research Grants ‡ RESPECT and AMULET	Significant (>= \$5,000)	Invasive CV Angio and Interventions
Tendyne	Data Safety Monitoring Board	Modest (< \$5,000)	Valvular Heart Disease

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (8)

Trial Name	Trial Sponsor	Trial Funding Source
COAPT Trial	Abbott Laboratories	
SUMMIT	Abbott Laboratories	
Triluminate: Triscupid Clipping	Abbott Vascular	
CLASP dMR and fMR	Edwards Life Sciences	
ACTIVE	Edwards Lifesciences	
PARTNER 2	Edwards Lifesciences	
REDUCE trial	Gore	
Low Risk TAVR versus SAVR	MEDTRONIC	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2016	Appropriateness of PFO closure	Defendant	Appropriateness of PFO closure following neurological events	Modest (< \$5,000)
2016	Outcome after cardiac surgery	Defendant	Death after CABG	Modest (< \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/18/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/18/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/18/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/18/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.